Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
關鍵詞
抽象
描述
Astragalus membranaceus (AM, Huang-Chi) is a Chinese herb used extensively in China as a traditional treatment to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. Our previous studies have demonstrated enhanced recovery of neurologic function in patients with acute hemorrhagic stroke who received AM. It is hypothesized that AM either reduces inflammatory response or reduces perihematomal edema.
Subarachnoid hemorrhage secondary to rupture of a cerebral aneurysm is a medical condition associated with a high morbidity and mortality; approximately 10-15% of patients die before reaching medical care, and overall mortality is approximately 45%. Of those that survive, 30% suffer permanent disability graded as moderate to severe, and two-thirds of survivors never return to the same quality of life as they had prior to their hemorrhage. A large number of patients (30-70%) who are able to make it to the hospital and have successful treatment of their aneurysm will develop delayed cerebral vasospasm that is related to the blood clot from their initial aneurysm rupture. Of patients that survive their initial aneurysm rupture, vasospasm results in an additional 7% mortality and another 7% of severe disabilities secondary to ischemic strokes from severe spasm of cerebral arteries.
This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients. All procedures done as a part of this study are standard hospital care procedures done to treat aneurysmal subarachnoid hemorrhage according to the AHA/ASA guideline.
日期
| 最後驗證: | 07/31/2017 |
| 首次提交: | 08/20/2017 |
| 提交的預估入學人數: | 08/30/2017 |
| 首次發布: | 09/04/2017 |
| 上次提交的更新: | 08/30/2017 |
| 最近更新發布: | 09/04/2017 |
| 實際學習開始日期: | 08/31/2017 |
| 預計主要完成日期: | 08/31/2020 |
| 預計完成日期: | 08/31/2020 |
狀況或疾病
干預/治療
Drug: AM group
Drug: Placebo group
相
手臂組
| 臂 | 干預/治療 |
|---|---|
| Experimental: AM group Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment. | Drug: AM group This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients. |
| Placebo Comparator: Placebo group Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment. | Drug: Placebo group as a comparator comparing with AM group |
資格標準
| 有資格學習的年齡 | 20 Years 至 20 Years |
| 有資格學習的性別 | All |
| 接受健康志願者 | 是 |
| 標準 | Inclusion Criteria: - Patients who admitted to the hospital within 24 hours of onset of aneurysmal subarachnoid hemorrhage (SAH) stroke - Subarachnoid hemorrhage documented on head CT - Hunt Hess Grade 1-4 - Both Male and Female - Age more than 20 and less than 80 years older - Informed consent obtained from a patient or legal representative before enrollment Exclusion Criteria: - Traumatic or mycotic aneurysms - Complication of serious heart or hepatic disease or infection or renal failure - Malignant tumor - Patients judged to be inappropriate by physician in charge - Pregnant / breast feeding women - Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening - Ever stroke, and mRS≧3 |
結果
主要結果指標
1. Clinical symptom [90 days post discharge following AM treatment for aneurysmal subarachnoid hemorrhage]
次要成果指標
1. IL-6 [14 days post discharge following AM treatment for aneurysmal subarachnoid hemorrhage]
2. IL-1β [14 days post discharge following AM treatment for aneurysmal subarachnoid hemorrhage]
3. TNF-α [14 days post discharge following AM treatment for aneurysmal subarachnoid hemorrhage]
4. S100-β [14 days post discharge following AM treatment for aneurysmal subarachnoid hemorrhage]
